Novo Nordisk (NVO) Stock Declines While Market Improves: Some Information for InvestorsZacks Investment Research • 10/27/26
Novo Nordisk Vs. Eli Lilly Q3 Preview: I'd (Now) Buy Both, But Lilly Is My Top PickSeeking Alpha • 10/27/26
Amgen vs. Novo Nordisk: Which Healthcare Giant's Stock Is a Better Buy in 2026?The Motley Fool • 10/27/26
US judge refuses to block Eli Lilly weight-loss drug ads, rules against Novo NordiskReuters • 10/26/26
GLP-1 boom in China, India, Brazil could create $22 bln market by 2035, J.P. Morgan saysReuters • 10/23/26
Eli Lilly Rises 4% While Foundayo Nears European Approval; Amgen and Novo Nordisk Edge Higher24/7 Wall Street • 10/20/26
Novo's next-generation obesity drug shows 25% weight loss in women in late-stage analysisCNBC • 10/20/26
Novo Down 11% in a Month: How Should Investors Approach the Stock Now?Zacks Investment Research • 10/12/26
Bristol Myers Squibb vs. Novo Nordisk: Which Healthcare Stock Is a Better Buy in 2026?The Motley Fool • 10/10/26
UBS Called Novo Nordisk a 'Value Trap.' Here's the Other Side of That Argument.The Motley Fool • 10/09/26